610-779-7001

Pharm Pro Facility Excellence Award

Pharmaceutical Procesing Facility Excellence Award 2014

Pharmaceutical Processing magazine named CPS a Facility Excellence  Award Winner in a ceremony at INTERPHEX 2014.

Winner: Custom Processing Services, Inc.

Category: Manufacturing Excellence

Facility: Plant 3, Reading, PA

Pharmaceutical Processing’s Facility Excellence Award

Custom Processing Services has  a strong track record of contract manufacturing in the pharmaceuticals marketplace. And on November 11, 2011 that  legacy was strengthened  with  the opening of a 42,000 square foot facility dedicated to GMP processing, with two unique GMP processing stations. This commitment to new  and innovative  manufacturing  technology and  processes  has  led to it being  recognized  as one of Pharmaceutical Processing’s Facility Excellence Award winners for 2014.

Pharmaceutical Processing Facility Excellence Award 2014Prior to this expansion, two similar rooms had been in operation for about 10 years at another of the company’s facilities. However, ·CPS soon realized that the increased number of requests for cGMP work had them at capacity. Additionally, they needed to expand their capabilities  in order to perform smaller scale trial work. This most recent expansion covered  both  needs  by providing:

  • A two-level clean room that houses a variety of mobile mills and blenders for new trial
  • A production-sized clean room that can be fitted with larger equipment in handling greater product  CPS recently added  cGMP blending  capabilities to this area with  2.5 CFT, 100 CFT and 300 CFT blenders that will allow CPS to meeting  a greater  range  of  batch  size requests.

Additional features of these clean rooms include sanitary mills, slant cone mills, tumblers and packaging stations, all of which can be configured  to a client’s  specific needs.

This expansion provides application coverage for a number  of  segments requiring cGMP-compliant production, including personal care items, food  grade  products, pharmaceutical excipients, active pharmaceutical ingredients  and  even  controlled  substances  such as  narcotics .

The entire facility was designed to handle up to nine more clean rooms in the   future.

Additionally, recent investments in various sizes of spiral style mills will allow for expanded pharmaceutical level micronizing. This means CPS can offer batch sizes as small as 10-50 grams, and as large as several metric tons. Other production and quality assurance-oriented investments include:

* A Biokill Heat Screw unit that breaks down microbiological agents to ensure products are safe for pharmaceutical use. This gives CPS an opportunity to take materials that may be considered technical grade and clean them to the point that they are acceptable as GMP ingredients.

* A stainless steel air classifier that provides a second step after micronizing to fine tune any desired particle range, if required. This system can remove any coarse materials so the product being packaged will meet more exacting specifications.

These investments not only allow for handling trial and production runs of various sizes and quantities, but the  new facility has also expanded testing and R&D functions  that include cleaning and process  validation. CPS feels that this range of production capabilities and end-product services allows them to cater to a customer’s specific needs in building a more personal relationship.

Along with investments in new production capabilities, CPS has looked to improve the quality of their operational processes. With this in mind the company recently unveiled a new safety system that is being applied to pharmaceutical grade products as part of the GMPs that are used on a daily basis. This includes a revised HACCP plan to ensure no foreign contaminants reach end-products, and all facilities now fall under a current ISO 9001 Quality Management System. CPS feels that this shows that they’re not only meeting, but exceeding customer requirements.

So as CPS looks to the future, they see opportunity in the changes  that  lie ahead. The  constantly  evolving  needs  of the pharmaceutical industry, in terms of new formulas, processes  and  regulations,  means  this  contract  manufacturer will need to continue to evolve and invest  in order to    keep pace. Their new facility and recent production equipment investments help reinforce that commitment.